Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant
Completed
Genentech, Inc.
Phase 2
2006-12-01
This is a 12-month phase 2, prospective, open label study to evaluate the effect of rituximab
with mycophenolate mofetil (MMF)on the PRA of 14 highly sensitized patients who just
completed an 8 month trial of MMF treatment alone. PRA values obtained at study enrollment
and at 6 and 12 months on combined therapy as well as the rates of transplant will be
compared and evaluated using descriptive analysis.
Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant
Completed
University of Washington
Phase 2
2006-12-01
This is a 12-month phase 2, prospective, open label study to evaluate the effect of rituximab
with mycophenolate mofetil (MMF)on the PRA of 14 highly sensitized patients who just
completed an 8 month trial of MMF treatment alone. PRA values obtained at study enrollment
and at 6 and 12 months on combined therapy as well as the rates of transplant will be
compared and evaluated using descriptive analysis.
TAP Catheters Versus Intrathecal Morphine for Cesarean Section
Unknown status
I-Flow
N/A
2012-05-01
Morphine, when given as part of spinal anesthesia, is associated high incidence of nausea and
pruritus, which may affect quality of recovery. The investigators hypothesize that
long-acting local anesthetic infusions via TAP catheter can provide better quality of
recovery after cesarean section than spinal morphine.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
